Table 1.
Level of evidence for BRAF alterations’ targetability according to OncoKB17
| Level | Gene | Alterations | Cancer types | Drugs |
|---|---|---|---|---|
| 1 | BRAF | V600 | Erdheim–Chester disease | Vemurafenib |
| 1 | BRAF | V600 | Melanoma | Vemurafenib + atezolizumab + cobimetinib |
| 1 | BRAF | V600E | All solid tumors (excluding colorectal cancer) | Dabrafenib + trametinib |
| 1 | BRAF | V600E | Anaplastic thyroid cancer | Dabrafenib + trametinib |
| 1 | BRAF | V600E | Biliary tract cancer, NOS | Dabrafenib + trametinib |
| 1 | BRAF | V600E | Colorectal cancer | Encorafenib + cetuximab |
| 1 | BRAF | V600E | Melanoma | Dabrafenib |
| 1 | BRAF | V600E | Melanoma | Vemurafenib |
| 1 | BRAF | V600E | Non-small-cell lung cancer | Dabrafenib + trametinib |
| 1 | BRAF | V600E, V600K | Melanoma | Dabrafenib + trametinib |
| 1 | BRAF | V600E, V600K | Melanoma | Encorafenib + binimetinib |
| 1 | BRAF | V600E, V600K | Melanoma | Trametinib |
| 1 | BRAF | V600E, V600K | Melanoma | Vemurafenib + cobimetinib |
| 2 | BRAF | Fusions | Pilocytic astrocytoma | Selumetinib |
| 2 | BRAF | Oncogenic Mutations (excluding V600) | Erdheim–Chester disease | Cobimetinib, trametinib |
| 2 | BRAF | Oncogenic Mutations (excluding V600) | Langerhans cell histiocytosis | Cobimetinib, trametinib |
| 2 | BRAF | Oncogenic Mutations (excluding V600) | Rosai–Dorfman disease | Cobimetinib, trametinib |
| 2 | BRAF | V600 | Langerhans cell histiocytosis | Vemurafenib, dabrafenib |
| 2 | BRAF | V600 (excluding V600E and V600K) | Melanoma | Dabrafenib + trametinib |
| 2 | BRAF | V600 (excluding V600E and V600K) | Melanoma | Encorafenib + binimetinib |
| 2 | BRAF | V600 (excluding V600E and V600K) | Melanoma | Vemurafenib + cobimetinib |
| 2 | BRAF | V600E | Colorectal cancer | Encorafenib + panitumumab |
| 2 | BRAF | V600E | Diffuse glioma | Vemurafenib + cobimetinib |
| 2 | BRAF | V600E | Encapsulated glioma | Vemurafenib + cobimetinib |
| 2 | BRAF | V600E | Hairy cell leukemia | Vemurafenib |
| 2 | BRAF | V600E | Pilocytic astrocytoma | Selumetinib |
| 2 | BRAF | V600E | Pleomorphic xanthoastrocytoma, Pilocytic astrocytoma, Ganglioglioma | Vemurafenib + cobimetinib |
| 3 | BRAF | Fusions | Melanoma | Trametinib, cobimetinib |
| 3 | BRAF | Fusions | Ovarian cancer | Trametinib, cobimetinib |
| 3 | BRAF | K601 | Melanoma | Trametinib |
| 3 | BRAF | L597 | Melanoma | Trametinib |
| 3 | BRAF | Oncogenic Mutations (excluding V600) | Histiocytosis | Cobimetinib, trametinib |
| 3 | BRAF | V600 | Histiocytosis | Vemurafenib, dabrafenib |
| 4 | BRAF | G464, G469A, G469R, G469V | All solid tumors | PLX8394 |
| 4 | BRAF | K601 | All solid tumors | PLX8394 |
| 4 | BRAF | L597 | All solid tumors | PLX8394 |